IQVIA Holdings Inc.
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total Revenue (FY2025) | $16,310 million (+5.9% YoY reported; +4.8% constant currency) |
| Net Income (GAAP, FY2025) | $1,360 million (vs. $1,373 million in FY2024) |
| Diluted EPS (FY2025) | $7.84 GAAP / $11.92 Adjusted |
| Operating Margin (FY2025) | 13.4% ($2,182M GAAP operating income / $16,310M revenue) |
| Adjusted EBITDA (FY2025) | $3,788 million (vs. $3,684 million in FY2024) |
| Free Cash Flow (FY2025) | $2,051 million (vs. $2,114 million in FY2024) |
| R&D Solutions Contracted Backlog | $32.7 billion (+5.3% YoY; book-to-bill basis) |
| Headcount | ~93,000 employees across 100+ countries |
| CRO Market Share (U.S., third-party estimate) | ~17.3% of U.S. CRO industry revenue (IBISWorld industry report, Sep 2025; U.S. market only, not an IQVIA-disclosed global figure) |
Sources: Revenue, segment, and profitability figures are from IQVIA Holdings Inc.'s Q4 and Full-Year 2025 earnings press release (furnished as Exhibit 99.1 to Form 8-K, filed with the SEC on February 5, 2026). Prior-year revenue figures (FY2021-FY2024) are from IQVIA's corresponding full-year earnings press releases for those years. IQVIA does not disclose segment-level operating income or profit, only segment revenue, so the segment pie reflects revenue only. The CRO market-share figure is a third-party estimate from IBISWorld's 'Contract Research Organizations' U.S. industry report (dated September 2025), covering only the U.S. market classification, not IQVIA's own disclosure and not a global figure; it is labeled accordingly.